BACKGROUND: Positron emission tomography (PET) with insulin-stimulated (18)F-2-deoxyglucose (FDG) uptake is the gold standard for myocardial viability. However, insulin stimulation is infrequently performed due to time and inconvenience. We therefore assessed the clinical applicability of an abbreviated hyperinsulinemic-euglycemic clamp. METHODS AND RESULTS: Dynamic FDG PET was performed in 50 patients with ischemic cardiomyopathy (ejection fraction: .30 +/- .10) using an abbreviated hyperinsulinemic-euglycemic clamp with separate Non-Diabetic (n = 26) and Diabetic (n = 24) protocols (American Society of Nuclear Cardiology guidelines), and supplemental potassium. In regions with normal resting perfusion ((13)N-ammonia uptake >or=80% maximal segment), there were no differences in either maximal (Non-Diabetic: .60 +/- .20 vs Diabetic: .60 +/- .17 micromol/min/g, P = .93) or mean rates of myocardial glucose uptake (MGU) (Non-Diabetic: .52 +/- .18 vs Diabetic: .52 +/- .14 micromol/min/g, P = .63) between the protocols. Multivariate analysis showed that diastolic blood pressure alone (maximal MGU, r (2) = .20, P = .001) or with NYHA Heart Failure Class (mean MGU, r (2) = .25, P = .003) could account for some of the variability in normal-region MGU. Potassium supplementation safely attenuated the decline in plasma levels. CONCLUSIONS: This abbreviated hyperinsulinemic-euglycemic clamp produced similar MGU values in normal resting myocardium in non-diabetic and diabetic subjects, which are no different than published rates with a standard insulin clamp. Thus, this abbreviated approach is sufficient to overcome myocardial insulin resistance.
BACKGROUND: Positron emission tomography (PET) with insulin-stimulated (18)F-2-deoxyglucose (FDG) uptake is the gold standard for myocardial viability. However, insulin stimulation is infrequently performed due to time and inconvenience. We therefore assessed the clinical applicability of an abbreviated hyperinsulinemic-euglycemic clamp. METHODS AND RESULTS: Dynamic FDG PET was performed in 50 patients with ischemic cardiomyopathy (ejection fraction: .30 +/- .10) using an abbreviated hyperinsulinemic-euglycemic clamp with separate Non-Diabetic (n = 26) and Diabetic (n = 24) protocols (American Society of Nuclear Cardiology guidelines), and supplemental potassium. In regions with normal resting perfusion ((13)N-ammonia uptake >or=80% maximal segment), there were no differences in either maximal (Non-Diabetic: .60 +/- .20 vs Diabetic: .60 +/- .17 micromol/min/g, P = .93) or mean rates of myocardial glucose uptake (MGU) (Non-Diabetic: .52 +/- .18 vs Diabetic: .52 +/- .14 micromol/min/g, P = .63) between the protocols. Multivariate analysis showed that diastolic blood pressure alone (maximal MGU, r (2) = .20, P = .001) or with NYHA Heart Failure Class (mean MGU, r (2) = .25, P = .003) could account for some of the variability in normal-region MGU. Potassium supplementation safely attenuated the decline in plasma levels. CONCLUSIONS: This abbreviated hyperinsulinemic-euglycemic clamp produced similar MGU values in normal resting myocardium in non-diabetic and diabetic subjects, which are no different than published rates with a standard insulin clamp. Thus, this abbreviated approach is sufficient to overcome myocardial insulin resistance.
Authors: Stephen L Bacharach; Jeroen J Bax; James Case; Dominique Delbeke; Karen A Kurdziel; William H Martin; Randolph E Patterson Journal: J Nucl Cardiol Date: 2003 Sep-Oct Impact factor: 5.952
Authors: M Mäki; M Luotolahti; P Nuutila; H Iida; L M Voipio-Pulkki; U Ruotsalainen; M Haaparanta; O Solin; J Hartiala; R Härkönen; J Knuuti Journal: Circulation Date: 1996-05-01 Impact factor: 29.690
Authors: James A Fallavollita; Andrew J Luisi; Suzanne M Michalek; Arturo M Valverde; Robert A deKemp; Michael S Haka; Alan D Hutson; John M Canty Journal: Contemp Clin Trials Date: 2006-05-02 Impact factor: 2.226
Authors: Rob S B Beanlands; Graham Nichol; Ella Huszti; Dennis Humen; Normand Racine; Michael Freeman; Karen Y Gulenchyn; Linda Garrard; Robert deKemp; Ann Guo; Terrence D Ruddy; Francois Benard; André Lamy; Robert M Iwanochko Journal: J Am Coll Cardiol Date: 2007-10-10 Impact factor: 24.094
Authors: Andrew C T Ha; Jennifer M Renaud; Robert A Dekemp; Stephanie Thorn; Jean Dasilva; Linda Garrard; Keiichiro Yoshinaga; Arun Abraham; Martin S Green; Rob S B Beanlands; Michael H Gollob Journal: Circ Cardiovasc Imaging Date: 2009-09-17 Impact factor: 7.792
Authors: Mireille Lortie; Rob S B Beanlands; Keiichiro Yoshinaga; Ran Klein; Jean N Dasilva; Robert A DeKemp Journal: Eur J Nucl Med Mol Imaging Date: 2007-07-07 Impact factor: 9.236
Authors: Roni Nielsen; Anders Jorsal; Peter Iversen; Lars Tolbod; Kirsten Bouchelouche; Jens Sørensen; Hendrik Johannes Harms; Allan Flyvbjerg; Hans Erik Bøtker; Henrik Wiggers Journal: J Nucl Cardiol Date: 2016-07-29 Impact factor: 5.952
Authors: José Soares; Filadelfo Rodrigues Filho; Marisa Izaki; Maria Clementina P Giorgi; Rosa M A Catapirra; Rubens Abe; Carmen G C M Vinagre; Giovanni G Cerri; José Cláudio Meneghetti Journal: Int J Cardiovasc Imaging Date: 2013-11-20 Impact factor: 2.357
Authors: James A Fallavollita; Brendan M Heavey; Andrew J Luisi; Suzanne M Michalek; Sunil Baldwa; Terry L Mashtare; Alan D Hutson; Robert A Dekemp; Michael S Haka; Munawwar Sajjad; Thomas R Cimato; Anne B Curtis; Michael E Cain; John M Canty Journal: J Am Coll Cardiol Date: 2013-09-25 Impact factor: 24.094